Lars Nilsson (Former)
1 – 23 of 23
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Analysis of erythroid maturation in the nonlysed bone marrow with help of radar plots facilitates detection of flow cytometric aberrations in myelodysplastic syndromes
(
- Contribution to journal › Article
- 2018
-
Mark
Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7
(
- Contribution to journal › Article
- 2017
-
Mark
Linear decline of corrected platelet count increment within 24 hours after platelet transfusion in haematological patients : a prospective observational study
(
- Contribution to journal › Article
-
Mark
Ataxia-pancytopenia syndrome with SAMD9L mutations
(
- Contribution to journal › Article
- 2014
-
Mark
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
2014) In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis 38(12). p.1381-1391(
- Contribution to journal › Scientific review
-
Mark
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
(
- Contribution to journal › Article
-
Mark
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo.
(
- Contribution to journal › Article
- 2011
-
Mark
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
(
- Contribution to journal › Article
- 2010
-
Mark
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
(
- Contribution to journal › Article
-
Mark
Persistent malignant stem cells in del(5q) myelodysplasia in remission.
(
- Contribution to journal › Article
- 2009
-
Mark
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
(
- Contribution to journal › Published meeting abstract
-
Mark
Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)
(
- Contribution to journal › Published meeting abstract
-
Mark
Expression of P53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5Q)
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0257-0257(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Long Term Efficacy And Tolerability Of Anagrelide In Myeloproliferative Disorders
2008) 13th Congress of the European-Hematology-Association In Haematologica-The Hematology Journal 93. p.0746-0746(
- Contribution to journal › Published meeting abstract
- 2007
-
Mark
The molecular signature of MDS stem cells supports a stem-cell origin of 5q - myelodysplastic syndromes
(
- Contribution to journal › Article
-
Mark
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
(
- Contribution to journal › Article
-
Mark
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
(
- Contribution to journal › Article
- 2005
-
Mark
IFN-{gamma} Negatively Modulates Self-Renewal of Repopulating Human Hemopoietic Stem Cells.
(
- Contribution to journal › Article
-
Mark
Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
(
- Contribution to journal › Article
- 2004
-
Mark
MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
(
- Contribution to journal › Article
-
Mark
Identification and Characterization of Stem Cells in Preleukemia and Leukemia
2004)(
- Thesis › Doctoral thesis (compilation)
- 2002
-
Mark
Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
(
- Contribution to journal › Article
- 1999
-
Mark
Distinct requirements for optimal growth and In vitro expansion of human CD34(+)CD38(-) bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells
(
- Contribution to journal › Article